Ultrasound-Driven Cavitation Reprograms Drug Response and Immune Sensitivity in Neuroendocrine Prostate Cancer

/in /by

Acoustic cavitation is emerging as a surprisingly powerful tool in the therapeutic landscape of neuroendocrine prostate cancer (NEPC), a disease state notoriously resistant to conventional treatments. By combining nanometer-scale lipid microbubbles with targeted ultrasound, researchers are leveraging a physical mechanism to overcome some of the most entrenched biological barriers in aggressive prostate cancer. At its […]

Read more

Tipifarnib Shows Early Promise as an Adjuvant in Enzalutamide-Resistant Prostate Cancer

/in /by

Tipifarnib is an interesting repurposing candidate in advanced prostate cancer because it may interfere with a resistance mechanism that goes beyond androgen signaling alone. In a preclinical work presented during the AUA 2026 meeting, the drug reduced exosome release from aggressive castration-resistant prostate cancer cells, including 22Rv1 and CWR-R1, by about 30% at low dose, […]

Read more

ZNF281 Emerges as a Novel Driver and Therapeutic Target in Advanced Prostate Cancer

/in /by

ZNF281 is a Krüppel-type zinc-finger transcription factor previously implicated in cancer stemness, but its role in prostate cancer has remained largely unexplored. In a new study, researchers evaluated ZNF281 expression across human prostate cancer samples, including primary tumors, metastatic lymph nodes, and normal prostate tissue. The findings revealed significantly higher expression of ZNF281 in metastatic […]

Read more

NRG1-Driven Microenvironmental Resistance to PI3K Inhibition in Prostate Cancer

/in /by

Prostate cancer is driven not only by tumor genetics but also by dynamic interactions with the tumor microenvironment (TME). Although alterations in the PI3K pathway are common, especially in PTEN-deficient disease, clinical results with PI3K inhibitors, even when combined with androgen receptor (AR) blockade, have been underwhelming. New evidence suggests that resistance may be driven […]

Read more

Arginase 1 Suppression Makes Exercise Effective Against Prostate Cancer

/in /by

Exercise has consistently been linked to improved outcomes in prostate cancer, but the mechanisms behind this effect have remained unclear. A recent preclinical study provides a compelling explanation, identifying suppression of arginase 1 (Arg1) and modulation of arginine metabolism as key drivers of exercise-induced tumor control. Using a prostate-specific Pten-knockout mouse model, researchers observed that […]

Read more

IVMT-Rx-4: A New Experimental Drug That May Help Block Prostate Cancer Spread to Bone

/in /by

IVMT-Rx-4 is a preclinical stage experimental compound being studied for advanced prostate cancer, especially for cancer that spreads to bone. The basic idea is to interfere with a protein called MDA-9/Syntenin. This protein seems to help prostate cancer cells invade tissue, communicate with their environment, and settle in bone. By blocking that pathway, IVMT-Rx-4 may […]

Read more

A Promising Drug Pair for Treatment-Resistant Prostate Cancer

/in , /by

A recent preclinical study points to a potentially important strategy for advanced prostate cancer: combining two already-known drugs to attack the disease from different angles at the same time. The work focused on metastatic castration-resistant prostate cancer, one of the hardest forms of prostate cancer to treat because it often adapts after standard hormonal therapies […]

Read more

Scientists Identify SIRT1 as a Driver of Neuroendocrine Prostate Cancer

/in , /by

Researchers have identified SIRT1 as a promising new target in neuroendocrine prostate cancer, a rare but highly aggressive subtype that often develops after standard hormone therapy stops working. The finding is important because this form of prostate cancer is especially hard to treat and tends to behave more aggressively than typical androgen-driven disease. The study […]

Read more

Telmisartan: A Familiar Blood Pressure Pill with New Potential in Cancer Therapy

/in , /by

Telmisartan, a widely used blood pressure drug, has shown unexpected promise as a booster for cancer treatment. Preclinical research indicates that when telmisartan is combined with the PARP inhibitor olaparib, cancer cells accumulate more DNA damage and become more vulnerable to treatment, even if they do not carry the usual BRCA‑type DNA repair defects that […]

Read more

DNA‑barcoded Gold Nanoparticles that Deliver Therapy Directly to Cancer Cell Mitochondria.

/in , /by

Cancer drugs often fail not because they are weak, but because they never reach the exact place they are supposed to act, all the way down to the tiny structures inside tumour cells. Researchers at the National University of Singapore have developed a new way to search for nanoparticles that can carry treatment directly to […]

Read more